McCullough Kristen

29PUBLICATIONS
70CO-AUTHORS
Haematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Metabolic medicineLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Sep 18, 2026
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.

|Aug 23, 2026
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

|Apr 06, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.

Saubia Fathima, Lior Rokach, Nour Ghosoun

|Dec 13, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.

Naseema Gangat, Azeem Elbeih, Nour Ghosoun

|Oct 01, 2024
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.

Zhuoer Xie, Jenna Fernandez, Terra Lasho

|Apr 02, 2024
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.

Marissa Li, Anmol Baranwal, Mark Gurney

Pageof 5

Frequent Collaborators

20 joint publications

Mrinal Patnaik

18 joint publications

Naseema Gangat

17 joint publications

Ayalew Tefferi

14 joint publications

Mithun Vinod Shah